Fredun Pharmaceuticals Hits Record FY26 Profit, Announces Bonus Issue

Fredun Pharmaceuticals reported record financials for the fiscal year 2025-26, with total income soaring 40.08% to ₹639.12 crore from ₹456.27 crore in the previous year. Profit After Tax (PAT) saw a significant jump of 59.59% to ₹33.21 crore, up from ₹20.81 crore in FY25.

Reader Takeaway: Strong FY26 growth driven by efficiency and pet care; bonus issue signals confidence.

What just happened

Fredun Pharmaceuticals announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a 40.08% increase in total income to ₹639.12 crore and a 59.59% rise in standalone PAT to ₹33.21 crore. Consolidated PAT stood at ₹32.62 crore. EBITDA grew by 72.05% to ₹94.79 crore.

Why this matters

These record financials indicate robust operational performance and successful strategic initiatives, particularly in the pet healthcare segment. The substantial growth in income and profit, coupled with margin expansion and a credit rating upgrade, signals improved financial health and investor confidence.

The backstory

In the previous fiscal year (FY25), Fredun Pharmaceuticals had reported total income of ₹456.27 crore and PAT of ₹20.81 crore. The company has been focusing on expanding its diversified healthcare business, including its pet healthcare division 'One Pet Stop'.

What changes now

The company's Board of Directors recommended a 2:1 bonus issue, meaning two bonus shares for every one share held. They also recommended a final dividend of 7% (₹0.70 per share). Authorized share capital is proposed to increase from ₹10 crore to ₹50 crore to facilitate these corporate actions.

Risks to watch

The company is in the process of transferring unclaimed dividends and shares to the Investor Education and Protection Fund (IEPF) authority. The secretarial audit noted delays in this transfer as of March 31, 2026.

Peer comparison

While specific peer comparisons are not provided in the filing, Fredun Pharmaceuticals' reported growth figures in income and PAT suggest it is outperforming or growing faster than many in the diversified healthcare sector.

Context metrics (time-bound)

• Total Income FY26: ₹639.12 crore (up 40.08% from FY25)
• PAT FY26: ₹33.21 crore (up 59.59% from FY25)
• EBITDA Margin FY26: 14.83% (up from 12.08% in FY25)
• PAT Margin FY26: 5.20% (up from 4.56% in FY25)

What to track next

Investors will be keen to monitor the operationalization of the new 40,000 sq. ft. manufacturing facility, expected in October 2026. Continued integration and performance of acquired businesses like 'One Pet Stop' will also be crucial.